You are here: Home » News-CM » Companies » News
Business Standard

Jubilant Life Sciences provides update on subsidiary - Jubilant Pharma

Capital Market 

Board of Jubilant Pharma approves of speciality pharma business in US

Jubilant Life Sciences announced that the Board of Jubilant Pharma (JPL), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential of a specialty pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, March 21 2017. 09:04 IST